The Promise of Improving  Hepatocellular Carcinoma Treatment Responses through Translational Device Testing

Treatment of unresectable hepatocellular carcinoma (HCC) is complex, and there is limited consensus on the optimal nonsurgical management strategy. This is further complicated by new technologies and locoregional therapies (LRTs) that continue to evolve over time. Several medical specialists are involved in HCC diagnosis and treatment, and treatment strategies are often dictated by consulting physicians ’ specialties, rather than by evidence-based consensus. The most recent National Comprehensive Cancer Network Clinical Practice Guidelines recommend ablation approaches for tumors 5 cm in size (1).
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Commentary Source Type: research